SLV-324
/ Solve Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 17, 2025
Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors
(Businesswire)
- "This latest funding follows a $75 million financing completed in December 2024, bringing Solve’s total capital raised to $321 million....Financing accelerates development of clinical-stage assets SLV-154 and SLV‑324, both featuring Solve’s CloakLink linker technology."
Financing • Solid Tumor
1 to 1
Of
1
Go to page
1